SynthesisEndocrine-related cancer2026
Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women.
Synthesis in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anabolics in Cancer Patients: To Use or Not to Use?Endocrinology and metabolism (Seoul, Korea) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid hormone-related protein (PTHrP) is produced by normal breast epithelial cells and is a cause of hypercalcemia in breast and other cancers. However, there are conflicting data regarding its role(s) in breast cancer biology. This study aimed to clarify PTHrP's potential function(s) in breast cancer by systematically examining its association with tumor characteristics, patient outcomes and hypercalcemia in women. We designed a predetermined strategy based on PRISMA 2020 guidelines. Seven databases were interrogated to identify studies of women with breast cancer reporting associations between tumor or circulating PTHrP levels and prognostic factors, calcium levels, relapse and survival. The ROBINS-E tool was used to examine the risk of bias. Quantitative syntheses of outcomes were performed by drawing forest plots of individual studies and pooling estimates. Forty-five studies met our eligibility criteria. We found that PTHrP is likely associated with positive progesterone receptor status, the presence of microcalcifications and lymph node invasion, but not with tumor type or grade. Most studies interrogating the association between PTHrP expression and breast cancer prognosis or hypercalcemia were at a very high risk of bias. Despite this, our results suggest associations between PTHrP and patient survival, the presence of bone metastases and the diagnosis of hypercalcemia of malignancy. These meta-analyses underscore the need for robust multivariate analyses in women to rigorously re-evaluate the role of PTHrP in breast cancer. This is important since the gene coding for PTHrP (PTHLH) has been consistently identified as a breast cancer susceptibility locus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.